160 related articles for article (PubMed ID: 38008573)
1. [Evaluation of the application value of seven tumor-associated autoantibodies in non-small cell lung cancer based on machine learning algorithms].
Hao Y; Wu LN; Lyu YT; Liu YZ; Qin XS; Zheng R
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Nov; 57(11):1827-1838. PubMed ID: 38008573
[No Abstract] [Full Text] [Related]
2. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
3. Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer.
Chen P; Lu W; Chen T
J Clin Lab Anal; 2021 Nov; 35(11):e24020. PubMed ID: 34555232
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of autoantibodies combined with tumor markers in the detection of lung cancer.
Mu Y; Li J; Xie F; Xu L; Xu G
J Clin Lab Anal; 2022 Aug; 36(8):e24504. PubMed ID: 35596744
[TBL] [Abstract][Full Text] [Related]
5. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
6. Clinical application of serum seven tumour-associated autoantibodies in patients with pulmonary nodules.
Hu K; Gao L; Zhang R; Lu M; Zhou D; Xie S; Fan X; Zhu M
Heliyon; 2024 May; 10(9):e30576. PubMed ID: 38765082
[TBL] [Abstract][Full Text] [Related]
7. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of Malignant Pulmonary Nodules Using a Combination of Tumor-associated Autoantibodies and Computed Tomography.
Liu X; Shen Q; Wen Y; Jiang Z; Ma Z; Zeng P; He J; Liao Y; Huang Y; Huang J
Am J Clin Oncol; 2024 Apr; 47(4):149-154. PubMed ID: 38054473
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
10. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
11. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
[TBL] [Abstract][Full Text] [Related]
12. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Value and Clinical Significance of Combined Detection of Serum Markers CYFRA21-1, SCC Ag, NSE, CEA and ProGRP in Non-Small Cell Lung Carcinoma.
Li Q; Sang S
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180443
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Diagnostic Value of CTC and CTDNA in Early Lung Cancer.
Hongwei Yao ; Lixin Wen ; Ziyan Li ; Chunwei Xia
Cell Mol Biol (Noisy-le-grand); 2023 Jun; 69(6):57-62. PubMed ID: 37605590
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Study to Determine Diagnostic Utility of 6 Commonly Used Lung Cancer Biomarkers Among Han and Uygur Population in Xinjiang Uygur Autonomous Region of People's Republic of China.
Yang-Chun F; Min F; Di Z; Yan-Chun H
Medicine (Baltimore); 2016 May; 95(18):e3568. PubMed ID: 27149479
[TBL] [Abstract][Full Text] [Related]
16. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892
[TBL] [Abstract][Full Text] [Related]
17. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
Tang ZM; Ling ZG; Wang CM; Wu YB; Kong JL
PLoS One; 2017; 12(7):e0182117. PubMed ID: 28750095
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Seven Clinical Tumor Markers in Diagnosis of Non-Small-Cell Lung Cancer.
Chen ZQ; Huang LS; Zhu B
Dis Markers; 2018; 2018():9845123. PubMed ID: 30647803
[TBL] [Abstract][Full Text] [Related]
20. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
